Skip to main content

Fiscal Wizard · Single-issue tearsheet

IMTX / Jun 22, 2026 Run #7584

IMTX

Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Composite verdict

B 63.1 / 100
Bullish setup · Reversal 8 drivers · 1 gate blocking
  • Parabolic SAR Flip
  • Declining Volume
  • Bollinger Reentry
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 40th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 15 signals0% Bear
Momentum Bullish 65Mean-reversion Bullish 81

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

30.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
P/B 75
Free Cash Flow Yield 0
Greenblatt ROC 71
P/S Ratio 25
Return on Capital Employed 66
EV/Sales 25

Technicals Bullish

95.9 / 100

Bullish setup leads (Parabolic SAR Flip, Declining Volume, Bollinger Reentry); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Parabolic SAR Flip 92
Declining Volume 86
Bollinger Reentry 83

Risk Gates

1 blocking 7 caution

1 guard active, 26 signals gated.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Sloan Ratio Caution

Visual accruals-quality flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for IMTX.